Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us    
Google
Web www.equitybulls.com
Stock Report

| More

Zydus announces completion of enrollment in three Phase III trials of Saroglitazar Magnesium in NASH

Posted On: 2019-07-18 11:58:14

Zydus Cadila, an innovation-driven, global pharmaceutical company, announced that it has completed enrollment in EVIDENCES 11, EVIDENCES 111 and EVIDENCES V Phase3 clinical trials of Saroglitazar Mg for treating Non-Alcoholic SteatoHepatitis(NASH). Patients with NASH have been enrolled in these trials across clinical sites in India and Mexico.

Speaking on the development Mr. Pankaj R. Patel, Chairman, Zydus group said, "We are excited about the progress that Saroglitazar Mg has been making in the NASH trials. It is currently being evaluated in over 23 different controlled clinical trials, involving over 3,800 patients. NASH is an area of unmet healthcare need and we are committed to develop this therapy for millions of patients suffering from this deadly disease.

EVIDENCES II is a Phase3 biopsy-driven trial of Saroglitazar 4 mg versus Placebo in patients with Non-Alcoholic SteatoHepatitis. The primary endpoint will be evaluated by histological improvementof NASH using liver biopsy at the end of 52 weeks.

EVIDENCES III is the prospective, multicenter, randomized, double-blind study of Saroglitazar 4 mg versus Placebo in patients with Non-Alcoholic Fatty Liver Disease(NAFLD). This trial will measure the change in liver fat content as measuredby non-invasive magnetic resonance imaging (MRI) at week 24. Several other secondary endpoints including Liver stiffness as measured by transient elastography / FibroScan® and Serum alanine aminotransferase (ALT) level will also be evaluated.

EVIDENCES V will evaluate the NASH patients over a period of 18 months, measure the change in the liver fat content by magnetic resonance imaging-derived proton density-fat fraction (MRIPDFF) at Week 24 and evaluatethe liver biopsy driven endpoints of Saroglitazar 4 mg from baseline to Week 76.

Saroglitazar Magnesium was launched in India during September 2013, for the treatment of hypertriglyceridemia and diabetic dyslipidemia in patients with type-2 diabetes not controlled by statins. Saroglitazar Mg has demonstrated beneficial effects in NASH animal models. Saroglitazar Mg favorably affects all components of NASH including steatosis, ballooning, inflammation and fibrosis in NASH models. Saroglitazar Mg has previously demonstrated improvelnent in both liver enzymes along with favorable effects on lipid and glycemic indices in patients with nonalcoholic fatty liver disease in PhaseII clinical trials.

Shares of CADILA HEALTHCARE LTD. was last trading in BSE at Rs.240.25 as compared to the previous close of Rs. 245.2. The total number of shares traded during the day was 88176 in over 1092 trades.

The stock hit an intraday high of Rs. 247 and intraday low of 238.6. The net turnover during the day was Rs. 21371852.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com





Other Headlines:

CNG supply, CNG-run vehicles and D-PNG supply launched in Ranchi

Insilco Ltd announces shut down of plant on high inventory

Ind-Ra revises rating outlook of Dynamatic Technologies Ltd

US FDA Inspection at Alkem's two manufacturing facilities

Cupid Ltd receives order of Rs. 4.95 crores

Trident Limited won 'Madhya Pradesh State Level 8th Kaizen Competition' Award

Supershakti Metaliks Ltd Board approves 1:1 Bonus Issue

Advik Laboratories Ltd to sell plant to pay for OTS with Indian Overseas Bank

Galaxy Surfactants' 'Aapda Rahat' CSR project extend flood relief aid to 1,000 families in Sangli

NHPC signs agreement with Assam Government for 2000 MW Hydro Power Project

NCL Industries Ltd to form JV in China

ICRA reaffirms ratings of Endurance Technologies Ltd

Bandhan Bank launches credit cards, in partnership with Standard Chartered Bank

IFFCO to invest Rs. 262.15 crore in Triumph Offshore Pvt. Ltd.

Wockhardt Ltd receives GMP compliance certificate for Ankleshwar unit

Thomas Cook India brings Domestic Tourism to the forefront

Hindustan Oil Exploration Company Ltd clarifies on stake sale by KMPs

Maruti Suzuki to proactively recall 40,618 WagonR (1 litre) vehicles

Sundaram-Clayton Ltd's plants to work only for 5 days in a week

Nilkamal Bito Storage Systems Pvt Ltd is now wholly owned subsidiary of Nilkamal Ltd

TVS Motor Company supports flood-affected states across India

Ishan Dyes & Chemicals Ltd allots 47,03,447 shares on rights basis

63 moons wins MPID case in Bombay HC, Court rules NSEL is not financial establishment

Brickwork Ratings revises ratings of Sical Logistics Ltd

TCS iON IntelliGem to Help School Students Build 21st Century Skills

Glenmark Pharmaceuticals receives ANDA approval for Fulvestrant Injection, 250 mg/5 mL (50 mg/mL)

Ethos Ltd opens new store at Phoenix Maret City, Velachery, Chennai

MEP Infrastructure Developers receives LOA for BOT project

India Ratings Places Shree Renuka Sugars on RWN

Infosys and University of Illinois Urbana-Champaign Enter a Strategic Partnership for Precision Medicine

Dabur India Ltd updates on new step down Subsidiary Company

Bimetal Bearings Ltd announces re-alignment of production

Amazon to acquire 49% in Future Coupons Ltd

Pidilite unveils state-of-the-art adhesive manufacturing plant in Bangladesh

HDFC Bank Ltd appoints Mr. Srinivasan Vaidyanathan as CFO

New Version of TCS iCMC™ Solution to Help Enterprises Accelerate their Cloud Journey

Kamdhenu Ltd starts partial manufacturing operations at paints factory, Alwar

Shreeji Translogistics Ltd Board to consider Interim Dividend & Bonus Issue

5paisa Capital Ltd allots shares on rights basis

KIOCL contributes to Chief Minister's relief fund

CARE downgrades ratings of Shivam Autotech Ltd

Commercial Syn Bags Ltd Board approves Dividend of Rs. 0.80

CRISIL revises outlook on long-term rating of BHEL

Gillette India Ltd appoints Mr. Gagan Sawhney as Additional Director

JK Super Cement announces association with Dabang Delhi as Team Title sponsor in Pro Kabaddi League 2019

Federal Bank Ties Up with Lulu Money, Hong Kong to Offer Instant Money Transfer to India

ITC Sunfeast Cup returns to Ladakh for an exciting second edition

Premier Ltd announces OTS of Rs. 31.17 crore for pending dues with Corporation Bank

Celebrity Fashions Ltd completes sale of property at GST Road, Chennai for Rs. 17 crores

Lupin launches Fluoxetine Tablets USP on receipt of US FDA approval







Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2019